FRFrida Rantanen

Frida Rantanen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Frida Rantanen has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Daniela Ungureanu

    Disease Networks Unit, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland

    3 shared publications
  • Astrid Murumägi

    Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland

    2 shared publications
  • Elina Multamäki

    Disease Networks Unit, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland

    2 shared publications
  • Adolfo J. Sáen Marín

    Instituto Ramón y Cajal de Investigación Sanitaria, Universidad de Alcala, Spain

    1 shared publication
  • Aino-Maija Kiiski

    Disease Networks Unit, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland

    1 shared publication
  • Alberto Alvarez-Larrán

    Department of Hematology, Hospital del Mar, Barcelona, Spain; Department of Hematology, Clinic Hospital, Barcelona, Spain

    1 shared publication

Latest Publications

  • Open Access

    Platelet proteome links metabolism to reactivity in Essential Thrombocythemia

    by Xiomara Guerrero-Carreño, Sanne Smits, Alfonso Esteban Lasso, Martina Samiotaki, Virtu Calabuig Navarro, Francisco José Iborra, Frida Rantanen, Alberto Alvarez-Larrán, Anna Angona Figueras, Beatriz Bellosillo, et al.

  • Open Access

    ROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancer

    by Juuli Raivola, Frida Rantanen, Alice Dini, Emilia Piki, Harlan Barker, Elina Multamäki, Franziska Bentz, Pia Sunkel, Aino-Maija Kiiski, Lassi Paavolainen, et al.

    Drug resistance remains a major challenge to durable responses in ovarian cancer, the fifth leading cause of cancer-related death among women. In this study, we developed long-term resistant (lt-res, several months) pre-clinical models of two drugs inducing mitotic arrest in TP53 -mutated cells: adavosertib (ADA), an investigational WEE1 inhibitor targeting the DNA damage response and currently evaluated in clinical trials, and paclitaxel (PTX), a widely used chemotherapeutic agent in cancer care targeting microtubules. Through integrated multi-omics functional profiling, we identify a shared PI3K/AKT-regulated signaling node that governs drug adaptation across all lt-res models. This node modulates the activity of DNA-damage responses and genotoxic stress to toggle between two adaptive states: activated PI3K/AKT driving a proliferative “fast-bypass” program with sustained cell cycle progression and mitotic evasion, or reduced PI3K/AKT signaling initiating a “slow-repair” state characterized by DNA damage checkpoint engagement, replication slowdown, and increased drug efflux. Notably, upregulation of receptor tyrosine kinases, such as ROR1, was observed in both ADA and PTX lt-res models with activated PI3K/AKT signaling. Targeting ROR1 with zilovertamab-vedotin, a monoclonal antibody-drug conjugate, resulted in enhanced cytotoxicity, demonstrating a new approach against recurrent drug-resistant ovarian cancer.


  • Open Access

    Precision targeting of CCNE1-amplified tumors—lessons from BLU-222 and beyond

    by Frida Rantanen, Daniela Ungureanu

    Editorial Commentary Precision targeting of CCNE1-amplified tumors—lessons from BLU-222 and beyond Frida Rantanen, Daniela Ungureanu


  • Open Access

    Molecular profiling of ex vivo prostate cancer CAF models captures stromal heterogeneity and drug vulnerabilities

    by Frida Rantanen, Astrid Murumägi, Mariliina Arjama, Katja Välimäki, Elina Multamäki, Tuomas Mirtti, Antti Rannikko, Teijo Pellinen, Daniela Ungureanu, Olli Kallioniemi

    Cancer-associated fibroblasts (CAFs) are central architects of the prostate cancer (PCa) microenvironment, yet their phenotypic diversity and druggable vulnerabilities remain largely uncharted. Here, we present an integrative multi-omics characterization of primary ex vivo CAFs from seven treatment-naïve PCa patients. Using single-cell RNA sequencing (scRNA-seq), we uncover substantial transcriptional heterogeneity among CAFs, with distinct gene expression programs related to extracellular matrix remodeling, inflammation, immune modulation, and metabolic reprogramming. This phenotypic diversity was further supported by variable expression of canonical stromal markers, including FAP, SULF1, VIM, CAV1, and αSMA. Transcription factor network analysis revealed SOX, FOX, and STAT3 family members as key regulators of pro-tumorigenic CAF states. To probe therapeutic vulnerabilities, we performed high-throughput drug sensitivity and resistance testing (DSRT) across 396 oncology compounds. CAFs exhibited broad sensitivity to multikinase inhibitors, with dasatinib, midostaurin, and FGFR inhibitors (AZD4547, erdafitinib) emerging as top stromal-directed candidates. These findings underscore the plasticity of prostate CAFs and reveal actionable vulnerabilities, supporting the development of targeted stromal therapies to disrupt tumor-stroma interactions in PCa.